fl-101
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 25, 2021 (NCT04758949)
Timeline
Indications
Mechanism of action
- Interleukin-1 betaINHIBITOR
IL1B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05395260 | Early Phase 1 (Phase 1) | Aug 22, 2022 | City of Hope National Medical Center, Flamel Technologies, Icahn School of Medicine at Mount Sinai |
| NCT04983732 | Phase 1 | Sep 11, 2021 | AXIS Clinicals Limited, Flamel Technologies |
| NCT04758949 | Phase 2 | Aug 25, 2021 | Flamel Technologies |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Flamel Technologies | For profit | 3 | 3 | 2 | 2021 |
| AXIS Clinicals Limited | For profit | 1 | 0 | 1 | 2021 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1